Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19
Open Access
- 16 March 2026
- journal article
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (4) , 1100-1112
Abstract
Azithromycin is a widely used antibiotic and was frequently used to treat hospitalized patients during the COVID-19 pandemic. The impact of empiric azithromycin use on the respiratory microbiome in patients with viral respiratory infections is unclear. Here we used longitudinal metatranscriptomics on nasal swabs from a prospective multicentre cohort of 1,164 patients hospitalized for COVID-19. We compared the upper respiratory microbiome, resistome and systemic immune response in patients treated with azithromycin ( n = 366) with those who received no antibiotics ( n = 474) or other antibiotics ( n = 324). We found that azithromycin altered microbiome composition and increased the expression and relative proportion of macrolide/lincosamide/streptogramin (MLS) resistance genes. These changes occurred after 1 day of exposure and persisted for over a week. MLS resistance gene expression was associated with commensals and potential pathogens, while there were no differences in host inflammatory gene expression in blood and airways. This demonstrates that empiric azithromycin treatment impacts the upper respiratory microbiome and resistome without apparent anti-inflammatory benefit.Keywords
All Related Versions
Funding Information
- Division of Intramural Research
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
This publication has 48 references indexed in Scilit:
- Cystic Fibrosis Pulmonary GuidelinesAmerican Journal of Respiratory and Critical Care Medicine, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell SequencingJournal of Computational Biology, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- High Frequency of Macrolide Resistance Mechanisms in Clinical Isolates of Corynebacterium SpeciesMicrobial Drug Resistance, 2010
- Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory MedicationsClinical Microbiology Reviews, 2010
- A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantationEuropean Respiratory Journal, 2010
- Fast and SNP-tolerant detection of complex variants and splicing in short readsBioinformatics, 2010
- Antimicrobial Susceptibility and Clinical Sources of Dolosigranulum pigrum CulturesAntimicrobial Agents and Chemotherapy, 2000